Abnormal Serum Bilirubin/Albumin Concentrations in Dementia Patients With Aβ Deposition and the Benefit of Intravenous Albumin Infusion for Alzheimer’s Disease Treatment
| Autor: | Hong Chen, Change Zhang, Naikeng Mai, Xuejun Wang, Weiru Zhang, Yuping Ning, Xingxiao Huang, Zhangying Wu, Caijun Li, Xinru Chen, Jinbao Liu, Xiaomei Zhong, Cong Ouyang, Ben Chen, Min Zhang, Wanyuan Liang, Weimin Lao, Qi Peng, Yuning Liao |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Bilirubin Clinical Dementia Rating lcsh:RC321-571 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine medicine Dementia lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry albumin Aβ deposition business.industry Dementia with Lewy bodies General Neuroscience Dopaminergic Albumin Repeated measures design medicine.disease 030104 developmental biology Endocrinology chemistry Apoptosis bilirubin business Alzheimer’s disease 030217 neurology & neurosurgery dementia |
| Zdroj: | Frontiers in Neuroscience, Vol 14 (2020) |
| ISSN: | 1662-453X |
| DOI: | 10.3389/fnins.2020.00859 |
| Popis: | Background Our previous study in animal models revealed that bilirubin could induce Aβ formation and deposition. Bilirubin may be important in neurodegenerative dementia with Aβ deposition. Hence, lowering the concentration of the free bilirubin capable of crossing the blood brain-barrier may benefit the treatment of Alzheimer's disease (AD). Objectives The objectives of this study were to examine the change in the serum bilirubin and albumin concentrations of dementia patients with Aβ deposition, and to determine the effects of intravenous administration of albumin in the treatment of AD. Methods Bilirubin and albumin concentrations in dementia patients with Aβ deposition were examined. Cell viability and apoptosis were determined in dopaminergic neuron-like cells MN9D treated with bilirubin in the presence of diverse concentrations of serum. Human albumin at a dose of 10 g every 2 weeks for 24 weeks was administered intravenously to AD patients to examine the effect of albumin on AD symptoms. Results Significantly higher indirect bilirubin (IBIL) concentrations, lower albumin concentrations, and higher ratio of IBIL to albumin (IBIL/ALB) were observed in dementia patients with Aβ deposition, including AD, dementia with Lewy bodies, and general paresis of insane. In vitro assays showed that bilirubin-induced injury in cultured dopaminergic neuron-like cells negatively depends on the concentration of serum in the culture medium. General linear model with repeated measures analysis indicated a main effect of group on the change in albumin concentrations and Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory scale (ADCS-ADL) scores, and the main effect of time and group, and group-by-time interaction on the change of Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) scores. Analysis of the combined data of the entire 28 weeks of assessment period using the area under curve convincingly showed significantly improvements in the change of albumin concentrations, ADCS-ADL scores, and CDR-SB scores. Conclusion IBIL and the IBIL/ALB ratio are significantly higher in dementia patients with Aβ deposition, and intravenous administration of albumin is beneficial to AD treatment. Trial registration The intervention study was registered at http://www.chictr.org.cn (ChiCTR-IOR-17011539). Date of registration: June 1, 2017. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|